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ABSTRACT	
Background:	 Whilst	 robust	 preclinical	 and	 postmortem	 evidence	 suggests	 that	 altered	
GABAergic	function	is	central	to	the	development	of	psychosis,	little	is	known	about	whether	
it	 is	 altered	 in	 subjects	 at	 ultra-high	 risk	 of	 psychosis,	 or	 its	 relationship	 to	 prodromal	
symptoms.	
Methods:	 Twenty-one	 anti-psychotic	 naïve	 UHR	 individuals	 and	 20	 healthy	 volunteers	
underwent	proton	magnetic	resonance	imaging	at	3T.	GABA	levels	were	obtained	from	the	
medial	 prefrontal	 cortex	 (MPFC)	 using	 MEGA-PRESS,	 and	 expressed	 as	 peak-area	 ratios	
relative	 to	 the	 synchronously-acquired	 creatine	 signal.	 GABA	 levels	 were	 then	 related	 to	
severity	of	positive	and	negative	symptoms	as	measured	with	the	Community	Assessment	of	
At-Risk	Mental	States.		
Results:	Whilst	we	found	no	significant	difference	in	GABA	levels	between	UHR	subjects	and	
healthy	controls	(P	=	.130),	in	UHR	individuals	MPFC	GABA	levels	were	negatively	correlated	
with	the	severity	of	negative	symptoms	(P	=	.013).	
Conclusion:	 These	 findings	 suggest	 that	 GABAergic	 neurotransmission	may	 be	 involved	 in	
the	neurobiology	of	negative	symptoms	in	the	UHR	state.	
	
	
Keywords:	Psychosis;	Magnetic	Resonance	Spectroscopy;	GABA;	Ultra-high	risk	of	psychosis;	
Negative	symptoms	
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INTRODUCTION	
Converging	evidence	from	postmortem	and	preclinical	studies	indicates	that	dysfunction	of	
the	gamma-aminobutyric	acidergic	(GABAergic)	neurotransmitter	system	plays	a	major	role	
in	the	pathophysiology	of	schizophrenia	(Marin,	2012).	Postmortem	research	has	
demonstrated	decreased	mRNA	expression	of	glutamic	acid	decarboxylase	(GAD)	and	
reduced	density	of	fast-spiking	parvalbumin-positive	(PV+)	interneurons	in	a	corticolimbic	
circuitry	involving	the	prefrontal	cortex	and	the	amygdala	in	schizophrenia	(Lewis	et	al.,	
2005;	Akbarian	and	Huang,	2006;	Benes,	2010).	Furthermore,	animal	models	of	psychosis	
suggest	a	link	between	disrupted	cortical	GABAergic	function	and	dysregulation	of	
subcortical	dopaminergic	signaling	characteristic	of	the	disorder	(Grace,	2010).	Such	models	
propose	that	inhibitory	disruption	would	underlie	not	only	dopamine-dependent	positive	
symptoms	of	psychosis,	but	would	also	influence	other	neural	pathways	(e.g.,	including	the	
basolateral	nucleus	of	the	amygdala,	or	the	medial	prefrontal	cortex,	MPFC)	putatively	
involved	in	the	development	of	the	negative	symptoms	of	psychosis	(Grace,	2016).	
Moreover,	the	role	of	GABA	in	the	development	of	psychosis	is	further	supported	by	
preclinical	evidence	that	peripubertal	(i.e.,	premorbid)	pharmacological	intervention	on	
GABA-Aa5	receptors	prevents	schizophrenia-like	GABA	cell	loss	and	blocks	the	development	
of	psychosis-like	features	in	adult	rats	(Du	and	Grace,	2013,	2016).		
	
From	animal	and	human	post-mortem	studies	it	may	thus	be	hypothesized	that	
cortical	GABAergic	function	is	reduced	in	schizophrenia,	and	that	this	abnormality	can	be	
detected	in	the	premorbid	stages	of	the	disorder	(Modinos	et	al.,	2015).	However,	recent	
meta-analytical	evidence	from	human	imaging	studies	using	proton	magnetic	resonance	
spectroscopy	(1H-MRS)	did	not	show	a	significant	difference	in	regional	GABA	levels	between	
patients	with	schizophrenia	and	healthy	volunteers	(Egerton	et	al.,	2017).	Research	in	
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patients	with	schizophrenia	is	complicated	by	previous	antipsychotic	exposure	and	
heterogeneity	of	clinical	subgroups	(Kegeles	et	al.,	2012).	In	this	context,	studies	in	subjects	
at	ultra-high	risk	of	developing	psychosis	(UHR)	are	a	useful	resource	to	investigate	
neurobiological	correlates	of	psychosis-like	characteristics	without	confounds	associated	
with	the	use	of	antipsychotics	or	illness	chronicity	on	the	imaging	data.	The	three	available	
MPFC	GABA	studies	in	UHR	individuals	have	also	presented	mixed	results,	including	
increases	(de	la	Fuente-Sandoval	et	al.,	2016),	decreases	(Menschikov	et	al.,	2016)	and	no	
differences	(Wang	et	al.,	2016)	when	compared	with	healthy	controls.	Nevertheless,	
heterogeneity	of	clinical	subgroups	is	also	a	potential	confounder	in	UHR	studies	(Fusar-Poli	
et	al.,	2016),	and	only	one	study	to	date	investigated	associations	between	GABA	levels	and	
severity	of	positive	and	negative	symptoms	in	this	group	(de	la	Fuente-Sandoval	et	al.,	
2016).	The	present	study	sought	to	address	these	issues	by	using	1H-MRS	in	a	homogenous	
sample	of	antipsychotic-naïve	subjects	at	UHR	of	psychosis	to	test	the	hypotheses	that:	(i)	
GABA	levels	in	the	MPFC	would	be	reduced	in	UHR	subjects	compared	with	healthy	controls	
(Marin,	2012),	and	that	(ii)	GABA	levels	would	be	inversely	related	to	the	severity	of	positive	
and	negative	prodromal	symptoms	(Grace,	2016).		
	
	
METHODS	
Procedures	were	approved	by	the	Research	Ethics	Committee	of	King’s	College	London	(KCL)	
and	South	London	and	Maudsley	NHS	Trust.	All	participants	provided	informed	consent.	
	
Twenty-one	UHR	individuals	and	20	healthy	volunteers,	all	males	aged	18–30	years,	
were	included.	UHR	psychopathology	was	assessed	using	the	Community	Assessment	of	At-
Risk	Mental	States	(CAARMS)	(Yung	et	al.,	2005).	UHR	inclusion	criteria	required	the	
presence	of	one	or	more	of	the	following:	(a)	attenuated	psychotic	syndrome,	(b)	a	brief	
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psychotic	episode	of	less	than	1	week’s	duration	that	spontaneously	remits	without	
antipsychotic	medication/hospitalization,	and	(c)	trait	vulnerability	(schizotypal	personality	
disorder	or	a	first-degree	relative	with	psychosis)	plus	a	marked	decline	in	psychosocial	
functioning.	Healthy	control	subjects	were	recruited	from	the	local	community.	They	were	
excluded	if	they	had	a	personal	or	familial	history	of	psychiatric	disorder,	neurological	
illness,	or	drug/alcohol	dependence	based	on	the	DSM-V	(American	Psychiatric	Association,	
1994).	Current/past	medication	use	and	current/past	use	of	tobacco	and	cannabis	was	
assessed	using	a	semi-structured	interview	adapted	from	the	Early	Psychosis	Prevention	and	
Intervention	Centre	(EPPIC)	Drug	and	Alcohol	Assessment	Schedule	
(http://www.eppic.org.au).	All	subjects	were	safe	for	MRI,	had	an	IQ	in	the	normal	range	as	
assessed	using	the	Wechsler	Adult	Intelligence	Scale-III	(WAIS-III)	(Velthorst	et	al.,	2013),	
were	antipsychotic-naïve,	and	none	were	taking	benzodiazepines.		
	
Subjects	underwent	1H-MRS	on	a	General	Electric	Signa	HDx	TwinSpeed	3T	scanner	
(Milwakee,	Wisconsin)	at	the	Centre	for	Neuroimaging	Sciences,	Institute	of	Psychiatry,	
Psychology	&	Neuroscience	(KCL).	GABA	levels	were	obtained	from	the	MPFC	using	MEGA-
PRESS,	which	incorporates	a	standardized	chemically	selective	suppression	(CHESS)	water	
suppression	routine	(TE	=	68ms,	TR	=	2000ms).	For	each	acquisition,	unsuppressed	water	
reference	spectra	(16	averages)	were	also	acquired.	Shimming	was	optimized,	with	auto-
prescan	performed	twice	before	each	scan.	The	region	of	interest	(ROI)	in	the	MPFC	was	
prescribed	from	the	midline	sagittal	localizer,	and	the	center	of	the	40	×	35	×	20mm	ROI	was	
placed	above	the	middle	section	of	corpus	callosum	(Figure	1A).	Spectra	were	analyzed	using	
LCModel	6.3-1L	with	the	basis	set	provided	by	its	author	(Provencher,	2016),	which	
contained	the	metabolites	GABA,	glutamine	(Gln),	Glutamate	(Glu),	Glx	(glutamate	+	
glutamine),	and	N-Acetyl-Aspartate	(NAA).	We	used	Cramer-Rao	minimum	variance	bounds	
(CRLB)	>	20%	as	reported	by	LCModel,	which	are	estimates	of	fit	of	the	metabolite	peaks,	
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and	signal-to-noise	ratio	(SNR)	<	8	to	exclude	poorly-fitted	metabolite	peaks	from	statistical	
analysis	(Mouchlianitis	et	al.,	2016;	Provencher,	2016).	Data	from	all	41	participants	in	the	
present	study	met	these	criteria.	Metabolites	were	expressed	as	ratios	relative	to	the	
synchronously-acquired	creatine	signal	from	the	unedited	MEGA-PRESS	spectra.	This	is	a	
well-established	normalization	procedure	in	clinical	1H-MRS	studies	which	has	been	
extensively	used	in	previous	studies	of	MPFC	GABA	levels	in	patients	with	schizophrenia	
(Goto	et	al.,	2009;	Ongur	et	al.,	2010;	Kegeles	et	al.,	2012;	Marsman	et	al.,	2014)	and	UHR	
subjects	(Marenco	et	al.,	2016;	Menschikov	et	al.,	2016).	
	
Analysis	of	demographic	and	metabolite	data	was	performed	with	SPSS	24	(Chicago,	
IL).	Group	differences	were	tested	using	independent-sample	t-tests	and	significant	effects	
are	reported	at	P	<	.05.	Associations	between	GABA/Cr	levels	and	severity	of	CAARMS	
positive	and	negative	symptoms	were	assessed	with	linear	regression	and	results	were	
Bonferroni-corrected	at	P	<	.025.	In	line	with	previous	studies	(e.g.,	(Kegeles	et	al.,	2012;	de	
la	Fuente-Sandoval	et	al.,	2016),	exploratory	analyses	on	the	other	metabolites	in	the	
spectra	(Glu/Cr,	Glx/Cr	and	NAA/Cr)	were	conducted	for	completion,	but	will	not	be	
discussed.	These	analyses	explored:	(i)	group	differences	using	t-tests,	(ii)	associations	with	
CAARMS	positive	and	negative	symptoms	using	linear	regression,	and	(iii)	correlations	
between	GABA/Cr	and	the	other	metabolites	using	Pearson’s	product-moment	correlation	
(Bonferroni-corrected	at	P	<	.05/3).	As	field	strengths	of	4T	or	more	are	needed	to	measure	
Gln	accurately,	exploratory	analysis	of	this	metabolite	was	not	performed	(Snyder	and	
Wilman,	2010).	Finally,	Pearson’s	product-moment	correlation	was	used	to	examine	
potential	associations	between	GABA	levels	and	age	as	well	as	cigarette	use	in	UHR	subjects,	
and	Mann	Whitney-U	was	used	to	examine	potential	group	effects	between	UHR	with	and	
without	current	or	past	cannabis	use.		
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RESULTS	
Table	1	summarizes	participant	characteristics	and	metabolite	values.	All	UHR	subjects	met	
Attenuated	Psychosis	Syndrome	criteria.		
	
GABA	Levels	
There	were	no	significant	differences	in	the	creatine-scaled	GABA	levels	between	UHR	
subjects	and	healthy	controls	(P	=	.130).	Exploratory	analysis	of	the	other	metabolites	in	the	
spectra	also	showed	no	significant	differences	between	groups	corrected	for	multiple	
comparisons	(all	P	>	.017)	(Table	1,	Figure	1B).		
	
[TABLE	1	ABOUT	HERE]	
	
Within	the	UHR	group,	MPFC	GABA/Cr	levels	were	inversely	associated	with	the	
severity	of	negative	symptoms	(ß	=	-.556,	t	=	-2.761,	P	=	.013,	significant	after	Bonferroni	
correction	at	P	<	.025),	but	there	was	no	relationship	with	positive	symptoms	(ß	=	-.245,	t	=	-
1.071,	P	=	.298)	(Figure	1C	and	1D).		
	
[FIGURE	1	ABOUT	HERE]	
	
MPFC	GABA/Cr	levels	were	not	significantly	associated	with	age	(r	=	-.027,	P	=	.908),	
cigarette	use	(r	=	-.195,	P	=	.410),	or	differed	in	UHR	subjects	with	current	or	past	cannabis	
use	compared	to	those	without	(current	use:	U	=	38.0,	Z	=	-1.723,	P	=	.085;	past	use:	U	=	
22.0,	Z	=	-.945,	P	=	.345).	Groups	did	not	differ	in	spectral	quality	(CRLB,	P	=	.484;	signal-to-
noise	ratio,	P	=	.939;	linewidth,	P	=	.778)	(Table	1).	Follow-up	clinical	data	revealed	that	3	of	
the	20	UHR	subjects	developed	psychosis	at	a	mean	follow-up	time	o	18	months.	
Exploratory	analyses	removing	these	subjects	rendered	the	correlation	between	GABA/Cr	
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and	CAARMS	negative	symptoms	no	longer	significant	(ß	=	-.377,	t	=	-1.578,	P	=	.135),	
suggesting	that	the	association	was	driven	by	those	individuals	who	went	on	to	develop	a	
psychotic	disorder.	
	
Other	Metabolites	
Exploratory	analysis	showed	no	significant	associations	between	levels	of	the	other	
metabolites	in	the	voxel	and	positive	or	negative	symptom	severity	(Glu/Cr	&	CAARMS	
positive:	ß	=	-.159,	t	=	-.684,	P	=	.503;	Glu/Cr	&	CAARMS	negative:	ß	=	-.297,	t	=	-1.283,	P	=	
.217;	Glx/Cr	&	CAARMS	positive:	ß	=	-.109,	t	=	-.463,	P	=	.649;	Glx/Cr	&	CAARMS	negative:	ß	=	
-.096,	t	=	-.400,	P	=	.694;	NAA/Cr	&	CAARMS	positive:	ß	=	-.173,	t	=	-.746,	P	=	.465;	NAA/Cr	&	
CAARMS	negative:	ß	=	-.034,	t	=	-.142,	P	=	.889).	None	of	these	metabolites	were	
significantly	correlated	with	age	(Glu/Cr:	r	=	-.296,	P	=	.192;	Glx/Cr:	r	=	-.421,	P	=	.058;	
NAA/Cr:	r	=	.342,	P	=	.130).	Finally,	Pearson’s	product-moment	correlation	showed	that	in	
healthy	controls	GABA/Cr	was	positively	associated	with	NAA/Cr	(r	=	.516,	P	=	.020),	while	in	
UHR	individuals	GABA/Cr	was	positively	associated	with	Glu/Cr	(r	=	.460,	P	=	.041).	However,	
these	associations	did	not	survive	Bonferroni	correction,	or	significantly	differed	between	
the	groups	(GABA	&	NAA:	z	=	1.7,	P	=	.089;	GABA	&	Glu:	z	=	-.69,	P	=	.490).	
	
	
DISCUSSION	 	
We	did	not	find	evidence	that	cortical	GABA	levels	(creatine-scaled)	in	subjects	at	UHR	of	
psychosis	differed	from	those	in	healthy	controls.	The	three	previous	GABA	MRS	studies	in	
UHR	subjects	reported	either	increased	(de	la	Fuente-Sandoval	et	al.,	2016),	decreased	
(Menschikov	et	al.,	2016),	and	no	difference	from	healthy	controls	(Wang	et	al.,	2016).	
Although	the	location	of	the	1H-MRS	voxel	in	those	previous	UHR	studies	was	more	ventrally	
placed	within	the	MPFC	than	in	our	study,	another	recent	study	in	unaffected	relatives	using	
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an	overlapping	voxel	to	ours	did	find	a	significant	decrease	in	the	relatives	(Marenco	et	al.,	
2016).	However,	these	were	asymptomatic	individuals	at	genetic	high	risk	as	opposed	to	a	
sample	of	subjects	with	an	attenuated	psychosis	syndrome.	Potential	sources	of	variability	
may	thus	relate	to	voxel	placement	and	to	the	nature	of	the	high-risk	sample	under	study.	
Future	studies	should	consider	standardizing	voxel	placement	or	using	multiple	rather	than	
single	voxels	(Duyn	et	al.,	1993).	Allowing	GABA	quantification	from	both	dorsal	and	ventral	
MPFC	in	the	same	individuals	would	help	elucidate	region-specific	effects	in	people	at	
increased	risk	for	psychosis	and	clarify	whether	GABA	function	is	relatively	uncompromised	
in	more	dorsal	MPFC	areas	compared	to	healthy	individuals.	Regarding	the	nature	of	the	
high-risk	samples	recruited	to	different	studies,	the	UHR	category	is	heterogeneous	with	
respect	to	both	inclusion	criteria	and	clinical	outcomes,	and	the	neuroimaging	findings	in	a	
sample	may	vary	depending	on	its	composition	(Fusar-Poli	et	al.,	2016).	In	this	context,	our	
study	expands	the	previous	literature	by	showing	results	from	a	homogeneous	sample	of	
UHR	individuals	who	all	fell	under	attenuated	psychosis	syndrome	criteria.	Prospective	
studies	in	similarly	homogenized	UHR	samples	are	needed	to	further	clarify	whether	
GABAergic	dysfunction	can	be	reliably	detected	in	this	group,	whether	the	MPFC	subregions	
affected	are	predominantly	ventral,	and	whether	alterations	in	GABA	levels	are	identifiable	
with	1H-MRS	in	UHR	individuals	who	are	destined	to	develop	a	psychotic	disorder.	
Nevertheless,	it	is	worth	noting	that	a	recent	meta-analysis	of	1H-MRS	studies	in	
schizophrenia	did	not	find	a	significant	effect	in	GABA	levels	(Egerton	et	al.,	2017),	
suggesting	a	lack	of	convergence	with	predictions	from	animal	and	postmortem	studies.	This	
might	relate	to	the	divergent	nature	of	the	measurements	across	disciplines.	While	
preclinical	and	postmortem	studies	suggest	that	the	GABAergic	abnormality	refers	to	PV+	
interneurons	(Marin,	2012),	1H-MRS	assesses	total	tissue	concentrations	and	as	such	it	is	
likely	to	not	be	restricted	to	a	particular	GABA	cell	type.	Future	translational	animal	and	
human	work	measuring	GABA	levels	in	homologue	regions	across	species	may	be	able	to	
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comprehensively	delineate	the	molecular	pathway	linking	GABAergic	dysfunction	to	the	
expression	of	schizophrenia-like	characteristics,	including	GABA	measurements	in	other	
anatomical	regions	such	as	the	hippocampus,	amygdala,	and	thalamus.	
	
Although	preclinical	models	would	primarily	predict	that	cortical	GABA	dysfunction	
leads	to	positive	psychotic	symptoms	through	a	hyper-responsive	dopamine	system	arising	
from	a	glutamatergic	dysregulation,	our	regression	analysis	did	not	reveal	an	association	
between	GABA	and	positive	symptoms.	However,	we	observed	that	GABA	levels	were	
significantly	inversely	associated	with	the	severity	of	negative	symptoms.	This	finding	is	of	
interest,	as	the	pathophysiological	basis	of	negative	symptoms	is	unclear	(Salamone	et	al.,	
2015),	and	it	merits	replication	in	a	larger	sample.	Previous	studies	had	not	found	a	
significant	association	between	MPFC	GABA	levels	and	severity	of	positive	or	negative	
symptoms	in	UHR	subjects	(de	la	Fuente-Sandoval	et	al.,	2016)	or	in	unmedicated	patients	
with	a	first-episode	of	psychosis	(Kegeles	et	al.,	2012).	Nevertheless,	as	mentioned	above,	
effects	of	anatomical	location	of	the	MEGA-PRESS	acquisition	and	study	sample	composition	
may	be	at	play.	Furthermore,	although	this	cross-sectional	study	was	not	designed	to	
examine	longitudinal	effects,	the	correlation	appeared	to	be	driven	by	UHR	individuals	who	
went	on	to	develop	a	psychotic	disorder.	Preclinical	models	have	proposed	circuit-based	
approaches	to	the	development	of	psychosis-like	behaviors	(Lisman	et	al.,	2008)	and	it	has	
been	recently	postulated	that	the	positive,	negative	and	disorganized	dimensions	of	
schizophrenia	may	originate	from	disruption	of	multiple,	interconnected	circuits	involving	
GABAergic	dysfunction	and	converging	on	hippocampal	hyperactivity	(Grace,	2016).	Hence,	
larger	multimodal	imaging	studies	in	UHR	subjects	investigating	associations	between	e.g.,	
GABA	levels	and	hippocampal	activity	in	relation	to	clinical	symptomatology	and	outcomes	
are	warranted	to	expand	the	present	findings.		
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Strengths	of	the	current	report	include	a	homogenous	UHR	sample	as	determined	
by	trained	clinicians,	a	well-matched	control	group,	and	a	validated	method	(MEGA-PRESS)	
to	quantify	water-scaled	GABA	concentrations	at	3T.	A	limitation	intrinsic	to	all	MEGA-PRESS	
studies	is	that	the	GABA	signal	contains	some	contribution	from	macromolecules,	i.e.	diverse	
proteins	and	lipids,	but	it	is	unlikely	that	the	macromolecule	contribution	would	differ	across	
groups.	Furthermore,	the	results	should	be	considered	in	the	context	of	a	sample	of	male	
participants	and	as	such	may	not	generalize	to	all	individuals	with	an	attenuated	psychosis	
syndrome.		
	
In	conclusion,	if	there	is	any	alteration	in	GABA	levels	measurable	with	in	vivo	1H-
MRS	in	the	MPFC	in	people	at	UHR	of	psychosis,	it	is	small	and	difficult	to	detect	even	with	a	
homogeneous	sample	of	antipsychotic-naïve	individuals.	Nevertheless,	our	data	provides	a	
direct	link	between	GABAergic	levels	and	prodromal	negative	symptoms,	which	warrants	
replication	in	larger	samples.
12	
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FIGURE	LEGEND	
	
	
Figure	1.	(A)	Voxel	placement	on	medial	prefrontal	cortex	(MPFC)	and	representative	sample	
1H-MRS	spectra.	(B)	MPFC	metabolite	levels	by	group.	(C)	Scatterplot	of	the	significant	
association	between	CAARMS	negative	symptom	severity	and	GABA/Cr	levels	(ß	=	-.556,	t	=	-
2.761,	R2	=	.310,	P	=	.013).	(D)	Scatterplot	of	the	non-significant	associations	between	
CAARMS	positive	symptom	severity	and	GABA/Cr	levels	(P	=	.298).	Cr,	creatine;	Glu,	
glutamate;	Glx,	glutamate	+	glutamine;	NAA,	N-Acetyl-aspartate;	UHR,	ultra-high	risk	of	
psychosis.		
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Table	1.	Participants’	characteristics	and	spectral	data.	
	 HC	(n	=	20)	 UHR	(n	=	21)	 HC	vs.	UHR	 	
	 Mean	(SD,	range)	 Mean	(SD,	range)	 Statistic	 p	 	
Age	(years)	 23.7	(2.7,	20-28)	 22.2	(3.0,	18-29)	 t	=	1.613	 .111	 	
Estimated	IQ	 117.1	(10.4,	95-132)	 110.0	(12.5,	75-128)	 t	=	1.736	 .092	 	
CAARMS	Positive	 -	 11.9	(6.7,	1-34)	 -	 -	 	
CAARMS	Negative	 -	 8.4	(6.4,	0-29)	 -	 -	 	
Tobacco	(cigarettes/day)	 -	 4.75	(6.7)	 -	 -	
Cannabis	now	(yes/no)	 -	 11/12	 -	 -	
Cannabis	ever	(yes/no)	 -	 16/4	 -	 -	
SNR	 21.6	(2.8)	 21.7	(2.80)	 -.076	 .939	
Line	width	 6.2	(1.8)	 6.4	(1.28)	 -.284	 .778	
GABA/Creatine	 .4	(.1)	 .3	(.05)	 1.546	 .130	
GABA	%	CRLB	 5.5	(1.0)	 5.9	(1.4)	 -1.052	 .300	
Glutamate/Creatine	 .5	(.1)	 5.5	(.1)	 -.769	 .446	 	
Glutamate	%	CRLB	 7.6	(1.5)	 6.6	(1.5)	 2.001	 .053	 	
Glx/Creatine	 .8	(.1)	 .8	(.1)	 -.255	 .800	 	
Glx	%	CRLB	 5.6	(1.4)	 5.2	(1.5)	 .835	 .409	 	
N-Acetyl-
Aspartate/Creatine	
1.1	(.1)	 1.1	(1.1)	 .823	 .415	 	
N-Acetyl-Aspartate	%	
CRLB	
1.15	(.37)	 1.63	(1.34)	 -1.512	 .146	 	
	
CAARMS,	Clinical	Assessment	for	At-Risk	Mental	States;	CRLB:	Cramer	Rao	Lower	Bounds;	
GABA,	gamma-aminobutyric	acid;	Glx,	glutamate	+	glutamine	ratio;	HC,	healthy	control	
subjects;	SNR:	signal	to	noise	ratio;	UHR,	ultra-high	risk	subjects.	
	
	
	
